公开(公告)号：US20250049829A1

公开(公告)日：2025-02-13

申请号：US18719989

申请日：2022-12-08

Applicant: ISTANBUL MEDIPOL UNIVERSITESI

Inventor： Ramazan KASMER ,  Metehan ILTER ,  Özge SENSOY ,  Nihal KARAKAS ,  Ozan TOPÇU

IPC: A61K31/704 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/506 ,  G16B15/30

Abstract: Disclosed are therapeutic molecules that can be used as an alternative to SHP2 phosphatase inhibitors, as a novel approach to targeting RAS isoforms with the G12D mutation that is involved in cancer formation.

公开(公告)号：US20250041301A1

公开(公告)日：2025-02-06

申请号：US18787713

申请日：2024-07-29

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Brian D. KLEIN ,  Hilde LAVREYSEN ,  Stefan Maria, Christiaan PYPE ,  Roy E. TWYMAN ,  Nancy Eulalie, Sylvain VAN OSSELAER ,  H. Steven WHITE ,  Marc André CEUSTERS ,  José Maria CID-NÚÑEZ ,  Andrés Avelino TRABANCO-SUÁREZ ,  Roger Francis BONE

IPC: A61K31/506 ,  A61K9/48 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K38/17 ,  A61K45/06 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18

Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.

公开(公告)号：US20240423908A1

公开(公告)日：2024-12-26

申请号：US18760128

申请日：2024-07-01

Applicant: Cyrano Therapeutics, Inc.

Inventor： Richard GEOFFRION ,  Ronald KUPPERSMITH

IPC: A61K9/00 ,  A61K31/198 ,  A61K31/4015 ,  A61K31/445 ,  A61K31/522 ,  A61K45/06 ,  A61K47/10 ,  A61K47/20 ,  A61K47/38 ,  A61P25/16 ,  A61P25/28

Abstract: Disclosed herein are methods of treating Parkinson's disease in a subject, comprising intranasally administering to the subject phosphodiesterase inhibitors and treatments for Parkinson's disease by a nasal spray device. Also disclosed herein are devices and kits for administering the compositions described herein to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction resulting from Parkinson's disease. Also described herein are treatments of other neurological diseases by a nasal spray device.

公开(公告)号：US20240368131A1

公开(公告)日：2024-11-07

申请号：US18754527

申请日：2024-06-26

Applicant: VENTUS THERAPEUTICS U.S. INC.

Inventor： Stéphane Dorich ,  Miguel ST-ONGE ,  Jason Burch ,  Ramsay Beveridge ,  Stéphane Ciblat ,  Alexandre CÔTÉ ,  Patrick Cyr

IPC: C07D403/12 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4439 ,  C07D209/34 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12

Abstract: The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

公开(公告)号：US20240366529A1

公开(公告)日：2024-11-07

申请号：US18307174

申请日：2023-04-26

Applicant: Cornell University

Inventor： Gareth R. Tibbs ,  Peter A. Goldstein ,  Anthony A. Sauve ,  Rajendra Uprety ,  James David Warren, JR. ,  Rebecca L. Joyce ,  Dipti N. Barman

IPC: A61K31/11 ,  A61K31/20 ,  A61K31/336 ,  A61K31/4015 ,  A61K47/64 ,  A61P25/04

Abstract: Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.

公开(公告)号：US20240293363A1

公开(公告)日：2024-09-05

申请号：US18376127

申请日：2023-10-03

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Michela Gallagher ,  Rebecca Haberman ,  Ming Teng Koh

IPC: A61K31/4015 ,  A61K31/19 ,  A61K31/20

CPC classification number: A61K31/4015 ,  A61K31/19 ,  A61K31/20

Abstract: This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).

公开(公告)号：US20240285598A1

公开(公告)日：2024-08-29

申请号：US18564748

申请日：2022-05-27

Applicant: Arun K. Ghosh ,  Monika Yadav ,  Andrew Mesecar

Inventor： Arun K. Ghosh ,  Monika Yadav ,  Andrew Mesecar

IPC: A61K31/4439 ,  A61K31/4015 ,  A61K31/4025 ,  A61P31/14 ,  C07D207/26 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D493/08

CPC classification number: A61K31/4439 ,  A61K31/4015 ,  A61K31/4025 ,  A61P31/14 ,  C07D207/26 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D493/08

Abstract: Disclosed are bis-amide inhibitors of SARS-CoV-2 (CO VID), and methods of using them to treat a severe acute respiratory syndrome.

公开(公告)号：US20240279172A1

公开(公告)日：2024-08-22

申请号：US18616873

申请日：2024-03-26

Applicant: Anivive Lifesciences, Inc.

Inventor： David Bruyette ,  Dylan Balsz

IPC: C07D207/12 ,  A61K9/00 ,  A61K31/4015 ,  A61K38/21 ,  A61K45/06 ,  A61P31/14

CPC classification number: C07D207/12 ,  A61K9/0053 ,  A61K31/4015 ,  A61K38/21 ,  A61K45/06 ,  A61P31/14

Abstract: The SARS-CoV-2 is highly contagious and has caused coronavirus disease 2019 (COVID-19) outbreaks worldwide. Some embodiments of the present invention relate to a method of ameliorating or treating a subject suffering from a SARS-CoV-2 infection. The method includes administering to the subject an antiviral composition comprising a therapeutically effective amount of a GC molecule or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12064488B2

公开(公告)日：2024-08-20

申请号：US17389674

申请日：2021-07-30

Applicant: The Regents of the University of California

Inventor： John Voss ,  Ruiwu Liu

IPC: A61K49/20 ,  A61K31/015 ,  A61K31/05 ,  A61K31/353 ,  A61K31/4015 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/53 ,  C07D207/14 ,  C07D207/20 ,  C07D207/273 ,  C07D491/052

CPC classification number: A61K49/20 ,  A61K31/015 ,  A61K31/05 ,  A61K31/353 ,  A61K31/4015 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/53 ,  C07D207/14 ,  C07D207/20 ,  C07D207/273 ,  C07D491/052

Abstract: The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

公开(公告)号：US12048696B2

公开(公告)日：2024-07-30

申请号：US17446387

申请日：2021-08-30

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Brian D. Klein ,  Hilde Lavreysen ,  Stefan Maria Christiaan Pype ,  Roy E. Twyman ,  Nancy Eulalie Sylvain Van Osselaer ,  H. Steven White ,  Marc André Ceusters ,  José Maria Cid-Núñez ,  Andrés Avelino Trabanco-Suárez

IPC: A61K31/506 ,  A61K9/48 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K38/17 ,  A61K45/06 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18

CPC classification number: A61K31/506 ,  A61K9/4858 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K38/1787 ,  A61K45/06 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/381 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00

Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.